SCHEDULE 13D/A: EcoR1 Capital Boosts Zymeworks Stake to 25.4%, Signaling Activist Intent and Board Influence

EcoR1 Capital, along with Oleg Nodelman, has increased its beneficial ownership in Zymeworks Inc. to 25.4%, asserting significant influence through board representation and a substantial investment in common stock and pre-funded warrants.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. collectively beneficially own 17,699,774 shares of Zymeworks Inc. Common Stock, representing 25.4% of the outstanding shares.
• This percentage is based on 69,576,883 shares outstanding as of March 3, 2025, as reported in Zymeworks' Form 10-K for the fiscal year ended December 31, 2024.
• The reporting persons acquired the shares for investment purposes, believing Zymeworks' Common Stock was undervalued and represented an attractive investment opportunity.
• Oleg Nodelman, manager of EcoR1, was appointed to Zymeworks' board of directors on February 17, 2025, and another EcoR1 employee, Scott Platshon, is also on the board.
• The Funds used their working capital to purchase Common Stock and Pre-Funded Warrants, investing $153,640,732.18 in Common Stock and $50,099,992.79 in Pre-Funded Warrants.
• They purchased 5,086,521 Pre-Funded Warrants on December 23, 2023, which are exercisable at $0.0001 per share but are subject to a 19.99% beneficial ownership limitation.
• Recent purchases of Common Stock occurred between March 18, 2025, and April 4, 2025, with dollar-weighted average prices ranging from $11.1679 to $13.0833 per share.
• A Registration Rights Agreement requires Zymeworks to register the resale of Warrant Shares, with deadlines for filing (earlier of March 15, 2024, and the first business day after Issuer files 2023 Form 10-K) and effectiveness (later of April 29, 2024, and the 123rd calendar day following the closing date).
• Zymeworks is liable for liquidated damages of 1% of the aggregate purchase price for shares held from exercised warrants for each 30-day period if registration deadlines are missed, capped at 6% in aggregate.

Sentiment

Score: 8

Explanation: The filing indicates a strong, strategic investment by a major fund, EcoR1 Capital, which has secured board representation and explicitly states a belief that the stock is undervalued. This suggests a positive outlook from a sophisticated investor, despite the inherent risks of the biotech sector and the beneficial ownership limitation on warrants.

Positives

• Significant investment by EcoR1 Capital, indicating strong belief in Zymeworks' undervaluation and long-term potential.
• EcoR1 Capital has secured two board seats, including its manager Oleg Nodelman, providing direct influence on corporate strategy and governance.
• The investor group has a clear strategy to monitor and potentially influence the company's operations, assets, and strategic matters, which could unlock shareholder value.

Negatives

• The Pre-Funded Warrants are subject to a 19.99% beneficial ownership limitation, restricting immediate full exercise and conversion into common stock, which limits the investor's immediate voting power.
• The Issuer faces potential liquidated damages if it fails to meet registration statement filing and effectiveness deadlines for the Warrant Shares, which could impact its financial performance.

Risks

• Beneficial Ownership Limitation: The 5,086,521 shares issuable upon exercise of Pre-Funded Warrants cannot be fully exercised at this time due to a 19.99% beneficial ownership limitation, which could restrict the reporting persons' ability to fully convert their investment and exert full voting power.
• Registration Statement Delays/Failures: If Zymeworks fails to file or make effective the registration statement for the resale of Warrant Shares by the specified deadlines, or if the statement becomes unavailable, the company will incur liquidated damages of 1% of the aggregate purchase price for exercised warrants per 30-day period, up to a maximum of 6%.
• Investment Volatility: The reporting persons' investment is subject to market fluctuations, and their stated intent to potentially purchase or sell additional shares, or engage in hedging, could contribute to stock price volatility.

Future Outlook

The reporting persons intend to routinely monitor Zymeworks Inc. regarding its operations, assets, prospects, financial position, and business development. They may take further actions, including purchasing or selling additional shares, entering into hedging transactions, or recommending strategic changes to management and the board, potentially involving mergers, acquisitions, or other changes in capitalization.

Management Comments

• "The reporting persons acquired the Stock for investment purposes based on their belief that the Issuer's Common Stock, when purchased, was undervalued and represented an attractive investment opportunity."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders."

Industry Context

This Schedule 13D filing indicates a significant activist investment in Zymeworks Inc., a biotechnology company. Such large stakes and board representation by investment firms like EcoR1 Capital are common in the biotech sector, where companies often face critical development milestones, M&A opportunities, or strategic shifts that can be influenced by major shareholders seeking to unlock value. The investment suggests a belief in Zymeworks' underlying value within the competitive biotech landscape.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Increased influence from a major activist investor (EcoR1 Capital) could lead to strategic changes aimed at enhancing shareholder value, but also potential volatility from large share purchases/sales and the investor's stated intent to potentially recommend significant corporate actions.
• Management/Board: Direct oversight and potential recommendations from EcoR1 Capital's representatives on the board will likely influence strategic planning and operational decisions, potentially leading to a more performance-driven approach.
• Creditors: No direct impact mentioned, but any significant strategic shifts (e.g., mergers, acquisitions, changes in capitalization) could indirectly affect the company's financial structure and risk profile.
• Employees/Customers/Suppliers: No direct impact mentioned, but any significant strategic shifts (e.g., mergers, acquisitions, changes in business development) could have future implications for these stakeholders.

Next Steps

• Reporting persons will routinely monitor Zymeworks Inc.'s operations, assets, prospects, financial position, and business development.
• Reporting persons may purchase additional Common Stock or sell existing holdings in the open market or privately.
• Reporting persons may enter into or unwind hedging or other derivative transactions with respect to the Common Stock.
• Reporting persons may pledge their interests in Common Stock to obtain liquidity.
• Reporting persons and their representatives may communicate with other stockholders, industry participants, and interested parties about Zymeworks Inc.
• Reporting persons may recommend actions to Zymeworks' management, board, and stockholders, potentially including mergers, acquisitions, or changes in capitalization.
• Zymeworks Inc. is obligated to use commercially reasonable efforts to cause the registration statement for the resale of the Warrant Shares to be declared effective as soon as practicable, but no later than the Effectiveness Deadline.

Key Dates

Recommendation

Keywords

Zymeworks Inc., EcoR1 Capital, Oleg Nodelman, Schedule 13D, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Investment Adviser, Biotechnology, SEC Filing, Corporate Governance, Shareholder Activism, Investment Strategy, Registration Rights Agreement